Federal Grant Award Summary

New York University School of Medicine received a $579,610 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective January 12, 2026, through December 31, 2030. The award supports research to elucidate the molecular and cellular mechanisms underlying LZTR1-related schwannomatosis, a rare neurogenetic disorder characterized by the development of multiple schwannomas (Schwann cell tumors) along peripheral nerves. Current treatment options are limited to neurosurgery and radiotherapy, with limited efficacy due to tumor recurrence and new lesion formation.

The research deliverables include the development of cellular and animal models of LZTR1-related schwannomatosis to study disease pathophysiology and identify potential therapeutic strategies. The investigation focuses on understanding how bi-allelic loss of the LZTR1 gene leads to accumulation of RIT1 and MRAS proteins and subsequent activation of downstream signaling pathways. Through these preclinical models, the research aims to identify pharmacological approaches to treat or prevent schwannoma formation, addressing a critical gap in therapeutic options for patients with this rare genetic disorder.